Related Experiment Video
Updated: Jan 22, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
The long noncoding RNA VIM-AS1 and nucleoporin Nup358/RanBP2 regulate SMAD nuclear accumulation during TGF-β
Dorival Mendes Rodrigues-Junior1, Mohamad Moustafa Ali1, Yuka Itoh1,2
1Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, SE-751 23 Uppsala, Sweden.
Abstract:
The transforming growth factor β (TGF-β) pathway is a developmental signaling network that regulates tissue homeostasis and malfunctions in human diseases, including cancer. TGF-β signals via two receptors, which activate SMAD and alternative signaling pathways. We show that TGF-β induces the expression of the mammalian long noncoding RNA (lncRNA) VIM-AS1 (Vimentin antisense RNA1) variant-2 (v.2) via a transcriptional SMAD-GATA6-SPI1 complex. VIM-AS1 v.1 and v.2 localize in different cell compartments, including the nuclear border. Unbiased whole transcriptomic analysis and functional gain and loss of function assays establish that VIM-AS1 v.2 enhances TGF-β signaling. Mechanistically, VIM-AS1 v.2 interacts with the nucleoporin Nup358/RanBP2, contributing to the binding of Nup358/RanBP2 to SMAD2/3 and enhancing SMAD nuclear accumulation. In the context of cancer biology, VIM-AS1 did not affect the antiproliferative actions of TGF-β, yet had an impact on the epithelial-mesenchymal transition gene program, and increased the invasion and motility of tumor cells, whereas its silencing sensitized cancer cells to chemotherapeutic agents. The molecular mechanism highlights how a lncRNA can modulate the nuclear pore's capacity to import SMAD complexes, by facilitating their capture by Nup358/RanBP2 and thereby enhancing nuclear accumulation of SMADs with distinct isoform composition, thus promoting selectively TGF-β signaling responses.
Insights
This study reveals that the long noncoding RNA VIM-AS1 variant-2 enhances transforming growth factor β (TGF-β) signaling by facilitating SMAD nuclear import. This mechanism impacts cancer cell invasion and chemoresistance.
Area of Science:
- Molecular Biology
- Cancer Biology
- RNA Biology
Background:
- The transforming growth factor β (TGF-β) pathway is crucial for tissue homeostasis and implicated in cancer.
- TGF-β signaling involves receptors activating SMAD and alternative pathways.
Purpose of the Study:
- To investigate the role of the long noncoding RNA VIM-AS1 in TGF-β signaling.
- To elucidate the molecular mechanism by which VIM-AS1 influences TGF-β pathway activity and cancer progression.
Main Methods:
- Transcriptomic analysis
- Functional gain and loss of function assays
- Interaction studies with nucleoporins and SMAD proteins
Main Results:
- TGF-β induces VIM-AS1 variant-2 expression via a SMAD-GATA6-SPI1 complex.
- VIM-AS1 variant-2 enhances TGF-β signaling by interacting with Nup358/RanBP2, promoting SMAD nuclear accumulation.
- VIM-AS1 variant-2 promotes cancer cell invasion and motility, and influences chemoresistance.
Conclusions:
- VIM-AS1 variant-2 acts as a key regulator of TGF-β signaling by modulating nuclear import of SMAD complexes.
- VIM-AS1 variant-2 plays a significant role in cancer progression and response to chemotherapy.
Related Concept Videos
TGF - β Signaling Pathway
Nuclear Export of mRNA
Regulation of Nuclear Protein Sorting
Nuclear Localization Signals and Import
Regulated mRNA Transport
Epigenetic Regulation

